Effect of temozolomide on survival in elderly patients with glioblastoma and impaired performance status: a propensity score–matching analysis
Authors Liu Y, Liu P, Shao W, Du H, Li Z, Guo C, Li Z
Received 29 September 2016
Accepted for publication 21 June 2017
Published 14 August 2017 Volume 2017:10 Pages 4029—4035
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Chiung-Kuei Huang
Yong-Liang Liu, Peng-Fei Liu, Wei Shao, Hong-Peng Du, Zhen-Zhu Li, Chong Guo, Ze-Fu Li
Department of Neurosurgery, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong, Yantai, People’s Republic of China
Objective: At present, there is no consensus regarding the standard treatment for glioblastoma (GBM) in elderly patients with impaired Karnofsky performance status (KPS) scores. This study aimed to determine the effects of temozolomide (TMZ) versus best supportive care (BSC) in this population.
Materials and methods: We conducted a retrospective observational study of patients aged ≥65 years with histologically confirmed GBM and KPS scores ≤70 who were treated at our institution between January 2006 and July 2014. Demographic data, treatments, and outcomes were evaluated. Univariate and multivariate analyses were performed to identify the independent prognostic factors of overall survival (OS) and progression-free survival (PFS). The impact of TMZ on survival was analyzed by the application of propensity score matching of clinicopathological factors among patients who received TMZ vs BSC.
Results: There were 153 patients (86 men, 56.2%) in this study. The median patient age was 70 years (range: 65–83 years). The median KPS score was 60 (range: 30–70). Seventy-eight patients (51.0%) received TMZ, whereas 75 (49.0%) received BSC. Median OS and PFS were 6.0 and 4.5 months, respectively. Compared with BSC, TMZ was associated with improved OS (hazard ratio [HR]: 0.38, 95% CI: 0.17–0.70; P=0.002) and PFS (HR: 0.41, 95% CI: 0.21–0.76; P=0.003) after propensity score matching. Factors independently associated with OS were KPS score (HR: 2.11, 95% CI: 1.48–7.67; P=0.016), extent of resection (HR: 1.98, 95% CI: 1.45–5.14; P=0.026), and treatment group (HR: 0.49, 95% CI: 0.23–0.87; P=0.019). The most frequent toxicity in the TMZ group was myelosuppression.
Conclusion: Compared with BSC, TMZ increased survival with acceptable toxicity in elderly GBM patients with KPS scores ≤70.
Keywords: temozolomide, best supportive care, elderly, glioblastoma, prognostic factors
Corrigendum for this paper has been published
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]